Compare NPO & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPO | IMVT |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.0B |
| IPO Year | 2002 | 2019 |
| Metric | NPO | IMVT |
|---|---|---|
| Price | $251.48 | $23.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $278.33 | $30.78 |
| AVG Volume (30 Days) | 188.1K | ★ 932.9K |
| Earning Date | 05-05-2026 | 02-06-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $1,532,000,000.00 | N/A |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | $6.39 | N/A |
| P/E Ratio | $131.22 | ★ N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $133.50 | $12.72 |
| 52 Week High | $286.35 | $29.25 |
| Indicator | NPO | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 32.65 |
| Support Level | $210.31 | $21.74 |
| Resistance Level | $286.35 | $24.63 |
| Average True Range (ATR) | 9.91 | 1.07 |
| MACD | -1.80 | -0.33 |
| Stochastic Oscillator | 52.51 | 1.68 |
Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through three segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.